Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.

As pouched products increase in popularity, researchers assess their pharmacology, harm-reduction potential, and initiation risk.

In part 2, Vanessa Slowey explains the pharmacy industry’s need for due diligence as technology reinforces patient convenience in the 21st century.

In this episode, Shawn Bjorndal, PharmD, RPh, and Jesse McCullough, PharmD, explore rhythms, routines and how they can make or break pharmacy team members.

Vanessa Slowey lays the ground for where AI and automation are impacting pharmacy practice today and discusses what innovations are still expected.

Presenting what they believe are the problems and solutions, PCMA CEO David Marin and NCPA CEO Douglas Hoey, RPh, discuss the US drug pricing dilemma.

Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.

The trial found that up to 25 days of nirmatrelvir-ritonavir did not improve cognitive, autonomic, or exercise-related symptoms compared with placebo.